- Home
- Publications
- Publication Search
- Publication Details
Title
Use of monoamine oxidase inhibitors in chronic neurodegeneration
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 13, Issue 2, Pages 233-240
Publisher
Informa UK Limited
Online
2016-12-21
DOI
10.1080/17425255.2017.1273901
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson’s disease
- (2016) Thomas Müller et al. JOURNAL OF NEURAL TRANSMISSION
- Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
- (2016) Thomas Müller Therapeutics and Clinical Risk Management
- Lewy Bodies: A Spectator or Salient Killer?
- (2015) Jeswinder Sian-Hulsmann et al. CNS & Neurological Disorders-Drug Targets
- A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients
- (2015) P. Barone et al. EUROPEAN JOURNAL OF NEUROLOGY
- Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression
- (2015) Makoto Naoi et al. JOURNAL OF NEURAL TRANSMISSION
- The Concept of Prodromal Parkinson’s Disease
- (2015) Philipp Mahlknecht et al. Journal of Parkinsons Disease
- Type A and B Monoamine Oxidase in Age-Related Neurodegenerative Disorders: Their Distinct Roles in Neuronal Death and Survival
- (2013) Makoto Naoi et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease
- (2013) Tamás Tábi et al. Expert Opinion on Drug Metabolism & Toxicology
- Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms
- (2013) Makoto Naoi et al. Expert Review of Neurotherapeutics
- Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease
- (2013) Thomas Müller Expert Review of Neurotherapeutics
- Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria
- (2013) Makoto Naoi et al. JOURNAL OF NEURAL TRANSMISSION
- Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity
- (2013) Jasmin Bartl et al. JOURNAL OF NEURAL TRANSMISSION
- Aldehyde dehydrogenase 2 in sporadic Parkinson's disease
- (2013) Tanja Maria Michel et al. PARKINSONISM & RELATED DISORDERS
- An update on amine oxidase inhibitors: Multifaceted drugs
- (2013) Mee-Sook Song et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
- (2013) Kay Teo et al. Translational Neurodegeneration
- Rasagiline
- (2012) Sheridan M. Hoy et al. DRUGS
- The PRIPS study: screening battery for subjects at risk for Parkinson's disease
- (2012) D. Berg et al. EUROPEAN JOURNAL OF NEUROLOGY
- Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease
- (2012) Thomas Müller et al. JOURNAL OF NEURAL TRANSMISSION
- Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells
- (2012) Keiko Inaba-Hasegawa et al. JOURNAL OF NEURAL TRANSMISSION
- The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?
- (2011) Jack J. Chen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties
- (2011) Federico Cacciapuoti JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Rasagiline-induced serotonin syndrome
- (2011) Carl Fernandes et al. MOVEMENT DISORDERS
- MAO-inhibitors in Parkinson's Disease
- (2011) Peter Riederer et al. Experimental Neurobiology
- Two polymorphs of safinamide, a selective and reversible inhibitor of monoamine oxidase B
- (2010) Krishnan Ravikumar et al. ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS
- Levodopa Deactivates Enzymes That Regulate Thiol−Disulfide Homeostasis and Promotes Neuronal Cell Death: Implications for Therapy of Parkinson’s Disease
- (2010) Elizabeth A. Sabens et al. BIOCHEMISTRY
- The relevance of iron in the pathogenesis of Parkinson’s disease
- (2010) Jeswinder Sian-Hülsmann et al. JOURNAL OF NEUROCHEMISTRY
- Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography
- (2010) Balázs Gulyás et al. NEUROCHEMISTRY INTERNATIONAL
- The Neurotoxicity of DOPAL: Behavioral and Stereological Evidence for Its Role in Parkinson Disease Pathogenesis
- (2010) W. Michael Panneton et al. PLoS One
- MAO-B INHIBITOR KNOW-HOW: BACK TO THE PHARM
- (2009) W. J. Burke et al. NEUROLOGY
- Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex
- (2008) C. C. Lapish et al. PSYCHOPHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now